Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence
- 5 August 2025
- journal article
- Published by Elsevier in International Journal of Drug Policy
- Vol. 145, 104934
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United StatesInternational Journal of Drug Policy, 2025
- Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017–21Health Affairs, 2023
- Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use DisorderJAMA Internal Medicine, 2018